West Pharmaceutical Services Shows Rising Relative Strength

On Tuesday, West Pharmaceutical Services (WST) earned an upgrade to its Relative Strength (RS) Rating, from 68 to 74. It currently resides comfortably on the IBD Long Term Leaders list.

When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.

IBD’s unique RS Rating measures market leadership by showing how a stock’s price action over the last 52 weeks compares to that of the other stocks in our database.

Decades of market research reveals that the top-performing stocks typically have an RS Rating of at least 80 as they launch their biggest runs. See if West Pharmaceutical Services can continue to rebound and clear that threshold.

Looking For Winning Stocks? Try This Simple Routine

The IBD Big Cap 20 stock has climbed more than 5% past a 312.22 entry in a first-stage consolidation, meaning it’s now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.

In terms of fundamental health, the company has posted rising EPS growth over the last six quarters. Sales gains have also risen during the same period.

West Pharmaceutical Services holds the No. 1 rank among its peers in the Medical-Supplies industry group.


Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders


Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button